Ten-Day Decitabine with Venetoclax vs Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score-Matched Analysis
BLOOD(2021)
摘要
Background: Patients (pt) with relapsed or refractory (R/R) acute myeloid leukemia (AML) have poor outcomes. Pts without actionable mutations (e.g. FLT3, IDH1/2) do not have standard approved treatments, and outcomes with available salvage therapies are poor (Roboz et al. J Clin Oncol. 2014). While venetoclax with azacitidine is now the standard for older or unfit pts with newly diagnosed AML, it is unknown how venetoclax-based lower intensity regimens compare to intensive chemotherapy (IC) for salvage therapy in adult pts with AML.
更多查看译文
关键词
AML,venetoclax,decitabine,intensive chemotherapy,relapsed,refractory
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络